EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Nolato AB (NLTBF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Nolato AB $4.38, price $5.50, upside -20.4%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN SE0015962477

NA Nolato AB logo Broad data Sep 24, 2026

Nolato AB

NLTBF · US

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value $4.38 · Overvalued (−20.4%)
✓Quality 63/100
!Weak Growth (revenue 5y +0.2 %/yr)
!Thin margins · 8.1% net margin (TTM)
✓Low debt · generates free cash flow
!Moderate moat 52/100

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.57 $3.22 Fair Value $4.38 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $3.22 – $7.57 · fair‑value band $2.52 – $6.74 · the $5.50 price screens above the $4.38 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. It operates through the Medical Solutions and Engineered Solutions segments.

Show more

Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. It operates through the Medical Solutions and Engineered Solutions segments. The company offers catheter balloons; breathing bags; non-conductive sealing and damping silicone products; primary plastic packaging for medicines; and crimp and dropper bottles. It also provides thermal heating pads, gap fillers, and paste under the Compatherm brand; Autolys M products, deep well plates, microtubes, PCR/qPCR products, pipettes and slim-line pipette tips, vial HP, and quality grades under the TreffLab by Nolato; and electromagnetic compatibility (EMC) products, including Compashield molded and extruded electromagnetic interference (EMI) shielding gaskets, Trishield, and MIL SPEC EMI shielding products. In addition, the company offers laboratory products, such as boxes with integrated lids; containers with hinged lids; sampling and transport tubes; spoons and cups; disposable tubes and containers; test tubes and ergonomic caps; and containers, vials, and slide tubes with push on lids. Further, it provides injection molding of plastic and silicone, injection blow molding, scientific and ceramic injection molding, dip and compression molding, and micro molding; extrusion and silicone sponge extrusion technologies; thermal management; decoration and cutting technologies; cleanroom production; assembly solutions; design and virtual prototyping solutions; and tool manufacturing. It serves medical technology, pharmaceutical, consumer electronics, telecom, automotive, hygiene, and other industrial sectors. The company was formerly known as Nordiska Latexfabriken i Torekov AB and changed its name to Nolato AB (publ) in 1982. Nolato AB (publ) was founded in 1938 and is headquartered in Torekov, Sweden.

Stock analysis

Nolato AB (NLTBF) currently trades at $5.50, while our model-based Fair Value estimate is $4.38, 20.4% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $5.67 per share, and 6 of the 26 models we run sit above the $5.50 price.

Bear case: the Growth DCF group reads lowest at $1.38, and 20 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: $2.52 (bear) to $6.74 (bull), the price of $5.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Nolato AB reported revenue of 9.5B SEK in FY2025 versus 11.6B SEK in FY2021, a compound −5.0%/yr. Reported net income was 777M SEK in FY2025, compounding −9.5%/yr from FY2021.

Key figures

Market cap $1.5B · P/E ratio 16.8 · P/S ratio 1.38 · EPS (TTM) $0.3000 · Net margin 8.2% · Return on equity 13.3% · Return on assets (EBIT) 9.9% · Revenue (TTM) 9.6B SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −20%, NLTBF screens richer than that median.

Fair Value models

Bear $2.52 Fair Value $4.38 Bull $6.74
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.2268 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $0.9700 $1.42 $1.99 81
Growth DCF $0.9900 $1.38 $1.87 79
Owner Earnings $2.02 $2.88 $3.98 77
All 26 models by family
DCF Models
FCF DCF $0.9700 $1.42 $1.99 81
Owner Earnings $2.02 $2.88 $3.98 77
5Y Revenue Exit $2.43 $4.22 $6.49 71
5Y EBITDA Exit $3.61 $6.36 $9.53 74
5Y P/E Exit $2.91 $5.10 $7.34 70
10Y Revenue Exit $1.71 $3.09 $4.92 65
10Y EBITDA Exit $2.48 $4.43 $6.98 67
10Y P/E Exit $2.08 $3.64 $5.49 63
Earnings-Based
Graham-Dodd $2.18 $5.85 $7.66 65
Lynch FV $1.14 $1.63 $2.12 61
PEG = 1.0 $1.14 $1.63 $2.12 57
EPV $2.52 $2.89 $3.20 74
Dividend Discount
Gordon GGM $1.29 $2.32 $3.20 68
DDM Multi-Stage $1.29 $1.89 $2.44 67
Multiples
P/E Multiple $5.04 $6.72 $8.40 63
P/S Multiple $4.08 $5.44 $6.80 58
P/B Multiple $4.08 $5.44 $6.80 55
EV/EBIT $5.21 $7.00 $8.79 66
EV/EBITDA $6.21 $8.34 $10.47 67
EV/Revenue $3.67 $5.31 $6.96 53
Asset-Based
NCAV (Graham) $1.14 $1.53 $2.28 54
Growth DCF
Growth DCF $0.9900 $1.38 $1.87 79
Rev-Margin DCF $2.43 $4.20 $6.13 72
Economic Profit
Residual Income $2.10 $2.45 $3.19 76
ROIC Compounder $2.56 $3.08 $3.65 72
Growth Earnings
Growth-Adj P/E $3.97 $5.67 $7.38 67

Open the full fair value analysis →

Notify me when NLTBF reaches fair value

Put NLTBF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 63/100

Of which business quality 61 · Market factors (momentum, volatility) 42

Profitability 52
Margins and returns on capital today
Quality Growth 53
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 74
Balance sheet, leverage, solvency risk
Investment 87
Disciplined investing over empire-building
Low Volatility 80
Calm price path (market factor)
Momentum 23
Price trend over the last 3–12 months (market factor)
52W Momentum 29
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−2.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−0.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.9%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.9% vs 7.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 11%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+32.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in SEK, Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +29.5% a year for the price and +4.2% for the forecasts.
Forecast 2026 (sales)+2.4%
Forecast 2027 (sales)+8.4%
Projected 2028 (sales)+7.6%
Projected 2029 (sales)+6.8%
Projected 2030 (sales)+6.0%

NLTBF screens overvalued: fair value 20% below the price. Compare with Abbott Laboratories, →

Compare Nolato AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nolato AB · Fair Value
$4.38 −20%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Nolato AB Fair Value". https://www.fairvalue-calculator.com/stock/NLTBF

Frequently asked questions

Is Nolato AB (NLTBF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $4.38 versus the last price from Sep 25, 2026 of $5.50, about −20% upside (overvalued).
What is the fair value of NLTBF?
Our model-based fair value for Nolato AB is $4.38 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $5.50.
What is the quality score of NLTBF?
Nolato AB has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nolato AB (NLTBF)?
Our model-based price target is the fair value of $4.38 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $2.52, optimistic scenario $6.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Nolato AB stock forecast for 2026?
Our models put fair value at $4.38, about −20% upside versus the last price from Sep 25, 2026 of $5.50 (overvalued). Cautious scenario $2.52, optimistic scenario $6.74. The calculation is refreshed regularly with new filings.
What is the revenue of Nolato AB (NLTBF)?
Nolato AB reported trailing-twelve-month revenue of about 9.6B SEK (latest available figure, as of Sep 24, 2026).
What growth is priced into Nolato AB (NLTBF)?
For today's price to be fair in a discounted-cash-flow model, Nolato AB would have to grow free cash flow by +32.0 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of NLTBF use?
Our models discount Nolato AB at 10.5 %: a base by market capitalisation (small), damped by beta 0.74, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nolato AB that is +32.0 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Nolato AB (NLTBF) delivered so far?
Over the past 5 years revenue at Nolato AB grew +0.2 % a year. The price currently implies +32.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Nolato AB (NLTBF) growing?
The median revenue growth in the sector is +7.0 % a year. That is the yardstick for the growth priced into Nolato AB (+32.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Nolato AB (NLTBF)?
The free-cash-flow yield on the price is 1.83 %: that much free cash flow Nolato AB produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Nolato AB (NLTBF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nolato AB it is $4.38 per share (as of Sep 24, 2026), against a price of $5.50. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Nolato AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, NLTBF trades above its calculated fair value: price $5.50, fair value $4.38, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NLTBF?
No. The price is what the market pays today ($5.50); the fair value is what the company's own numbers justify ($4.38). For Nolato AB the two are $1.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nolato AB worth?
The market values Nolato AB at about $1.5B (market capitalisation, as of Sep 24, 2026). Per share that is $5.50; our models calculate a fair value of $4.38 per share.
What do the bullish and bearish scenarios say about NLTBF?
Our models span a range for Nolato AB: cautious scenario $2.52, base $4.38, optimistic $6.74 per share (as of Sep 24, 2026, price $5.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is NLTBF from its 52-week high?
Nolato AB trades at $5.50, about 16% below its 52-week high of $6.53 and 12% above the low of $4.92 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $4.38 is for.
Which stocks are comparable to Nolato AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nolato AB stock attractive at the current price?
The data as of Sep 24, 2026: price $5.50, calculated fair value $4.38 (−20%), Quality Score 63/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NLTBF calculated?
We run Nolato AB through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Nolato AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nolato AB (NLTBF)?
The latest price we hold is from Sep 25, 2026 and stands at $5.50. Our model-based fair value is $4.38, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nolato AB right now?
The model range is unusually wide ($2.52 to $6.74). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Nolato AB (NLTBF) come from?
Earnings per share at Nolato AB grew +5.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.5 %, EBIT margin −2.0 %, tax rate −0.1 %, residual (interest, one-offs) −0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Nolato AB

How large is the market capitalisation of Nolato AB (NLTBF)?
The market capitalisation of Nolato AB is $1.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Nolato AB (NLTBF)?
The price-to-earnings ratio of Nolato AB is 16.8 (as of Jun 22, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Nolato AB (NLTBF)?
The price-to-sales ratio of Nolato AB is 1.38 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nolato AB (NLTBF)?
Earnings per share at Nolato AB are $0.3000 (price ÷ EPS = P/E 16.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nolato AB (NLTBF)?
The net margin of Nolato AB is 8.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nolato AB (NLTBF)?
The return on equity (ROE) of Nolato AB is 13.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nolato AB (NLTBF)?
On an EBIT basis the return on assets of Nolato AB is 9.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Nolato AB (NLTBF)?
Revenue at Nolato AB is growing −3.9% versus a year earlier (3y avg −4.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nolato AB (NLTBF)?
Earnings per share at Nolato AB are growing −9.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Nolato AB (NLTBF) carry?
The net debt of Nolato AB is 972M SEK (fiscal year 2025, ≈ 3.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.